Insmed stocks soar as Phase III lung disease drug exceeds expectations
If Insmed’s brensocatib is given the green light, it would be the first therapy approved for patients with bronchiectasis.
29 May 2024
29 May 2024
If Insmed’s brensocatib is given the green light, it would be the first therapy approved for patients with bronchiectasis.
SOM Biotech, a clinical-stage drug discovery and development company based on a unique proprietary Artificial Intelligent platform, has appointed George G Montgomery as Strategic Corporate Advisor to the Board.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.